CY1114673T1 - Παρασκευη και χρηση δισθενους εμβολιου εναντιον εθισμου μορφινης-ηρωινης - Google Patents
Παρασκευη και χρηση δισθενους εμβολιου εναντιον εθισμου μορφινης-ηρωινηςInfo
- Publication number
- CY1114673T1 CY1114673T1 CY20131101023T CY131101023T CY1114673T1 CY 1114673 T1 CY1114673 T1 CY 1114673T1 CY 20131101023 T CY20131101023 T CY 20131101023T CY 131101023 T CY131101023 T CY 131101023T CY 1114673 T1 CY1114673 T1 CY 1114673T1
- Authority
- CY
- Cyprus
- Prior art keywords
- morphine
- addiction
- heroin
- active vaccination
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Αποκαλύπτεται ο δομικός σχεδιασμός, μέθοδοι παρασκευής και χημική σύσταση δύο δομικών σκευασμάτων δισθενών εμβολίων εναντίον εθισμού μορφίνης-ηρωίνης (6-ημιηλεκτρική μορφίνη-ΕDC-TFCS-ανατοξίνη τετάνου και 3-Ο-καρβοξυμεθυλομορφίνη-ΕDC-TFCS-ανατοξίνη τετάνου). Αυτά τα εμβόλια είναι κατάλληλα για ανθρώπινη χρήση όπου είναι ικανά να προκαλούν την σύνθεση πολυκλωνικών αντισωμάτων εναντίον οπιούχου μορφίνης και του δομικού αναλόγου της, ηρωίνης, μέσω της επαναλαμβανόμενης χορήγησης in vivo αυτών των σκευασμάτων, σε πρωτόκολλα ενεργητικού εμβολιασμού, σε προκλινικές μελέτες σε τρωκτικά. Αποκαλύπτεται επίσης το πρότυπο ενεργητικού εμβολιασμού μέσω του οποίου αυτά τα ανοσογόνα προκαλούν χυμική ανοσοαπόκριση σταθεροποιημένη με μακροπρόθεσμη ανοσολογική μνήμη, που χαρακτηρίζεται από την παρουσία υψηλών τίτλων ειδικών αντισωμάτων εναντίον αυτών των δύο φαρμάκων κατάχρησης. Επιπλέον, η παρούσα εφεύρεση αποκαλύπτει την αποτελεσματικότητα αυτών των συζευγμένων σκευασμάτων σε πρόκληση παρατεταμένης ανοσοπροστασίας εναντίον εθισμού μορφίνης και ηρωίνης χρησιμοποιώντας πρότυπο ενδοφλέβιας αυτοχορήγησης αυτών των δύο οπιούχων ουσιών σε τρωκτικό. Τέλος, σχολιάζεται η δυνητική μελλοντική χρήση αυτών των ανοσοσυζευγμάτων σε πρωτόκολλα ενεργητικού εμβολιασμού για θεραπευτική αγωγή εθισμού μορφίνης και ηρωίνης σε ανθρώπους.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04006617A MXPA04006617A (es) | 2004-07-07 | 2004-07-07 | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
EP05761917.3A EP1767221B1 (en) | 2004-07-07 | 2005-07-05 | Preparation and use of a bivalent vaccine against morphine-heroine addiction |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114673T1 true CY1114673T1 (el) | 2016-10-05 |
Family
ID=35431510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101023T CY1114673T1 (el) | 2004-07-07 | 2013-11-20 | Παρασκευη και χρηση δισθενους εμβολιου εναντιον εθισμου μορφινης-ηρωινης |
Country Status (15)
Country | Link |
---|---|
US (4) | US8008457B2 (el) |
EP (1) | EP1767221B1 (el) |
AR (1) | AR049962A1 (el) |
BR (1) | BRPI0513024A (el) |
CA (1) | CA2573042C (el) |
CU (1) | CU23917B1 (el) |
CY (1) | CY1114673T1 (el) |
DK (1) | DK1767221T3 (el) |
ES (1) | ES2435769T3 (el) |
MX (1) | MXPA04006617A (el) |
PE (1) | PE20060377A1 (el) |
PL (1) | PL1767221T3 (el) |
PT (1) | PT1767221E (el) |
SI (1) | SI1767221T1 (el) |
WO (1) | WO2006004390A2 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
US8170546B2 (en) | 2006-03-22 | 2012-05-01 | Broadcom Corporation | Client device characterization of other client device transmissions and reporting of signal qualities to access point(s) |
EP1982729A1 (en) * | 2007-04-20 | 2008-10-22 | Cytos Biotechnology AG | Vaccination Regimen for B-Cell Vaccines |
US9125907B2 (en) * | 2009-09-30 | 2015-09-08 | Christopher Shaari | Use of botulinum neurotoxin to treat substance addictions |
CN102002049B (zh) * | 2010-10-12 | 2013-01-02 | 北京大学 | 一种抗原及其制备方法与应用 |
CN102539764A (zh) * | 2010-12-27 | 2012-07-04 | 北京库尔科技有限公司 | 盐酸哌替啶检测试剂盒及其制备方法 |
EP2717057A1 (en) * | 2012-10-04 | 2014-04-09 | Cisbio Bioassays | Morphine-6-glucuronide derivatives, immunogens and immunoassay |
RU2526807C2 (ru) * | 2012-11-28 | 2014-08-27 | Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА" | Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ |
US9127008B2 (en) | 2013-03-15 | 2015-09-08 | Johnson Matthey Public Limited Company | Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain |
US10262505B1 (en) * | 2013-12-03 | 2019-04-16 | Ca, Inc. | Anti-skimming solution |
US11305010B2 (en) | 2016-01-21 | 2022-04-19 | The Scripps Research Institute | Synthetic opioid vaccine |
WO2019094528A1 (en) | 2017-11-09 | 2019-05-16 | The Scripps Research Institute | An improved heroin vaccine |
WO2020012245A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Thienothiophene-naltrexone prodrugs for long-acting injectable compositions |
WO2020012248A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Novel naphthylenyl compounds for long-acting injectable compositions and related methods |
WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
RU2703494C1 (ru) * | 2018-11-12 | 2019-10-18 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Моноклональное антитело 6g1 к производным морфина |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH678394A5 (el) | 1990-08-22 | 1991-09-13 | Cerny Erich H | |
US6210677B1 (en) * | 1993-01-29 | 2001-04-03 | Robert C. Bohannon | Method to reduce the physiologic effects of drugs on mammals |
DE69630877T2 (de) | 1995-03-31 | 2004-11-11 | Xenova Research Ltd., Slough | Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie |
US20020032316A1 (en) * | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US5876727A (en) * | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
CN1069544C (zh) * | 1998-04-24 | 2001-08-15 | 昆明市生物技术工程研究中心 | 人用阿片类毒品戒毒疫苗 |
EP1597280B2 (en) * | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
MXPA04006617A (es) * | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
-
2004
- 2004-07-07 MX MXPA04006617A patent/MXPA04006617A/es active IP Right Grant
-
2005
- 2005-07-05 EP EP05761917.3A patent/EP1767221B1/en active Active
- 2005-07-05 ES ES05761917T patent/ES2435769T3/es active Active
- 2005-07-05 US US11/632,085 patent/US8008457B2/en not_active Expired - Fee Related
- 2005-07-05 WO PCT/MX2005/000049 patent/WO2006004390A2/es active Application Filing
- 2005-07-05 AR ARP050102788A patent/AR049962A1/es not_active Application Discontinuation
- 2005-07-05 PE PE2005000780A patent/PE20060377A1/es active IP Right Grant
- 2005-07-05 DK DK05761917.3T patent/DK1767221T3/da active
- 2005-07-05 BR BRPI0513024-7A patent/BRPI0513024A/pt not_active Application Discontinuation
- 2005-07-05 CA CA2573042A patent/CA2573042C/en active Active
- 2005-07-05 PL PL05761917T patent/PL1767221T3/pl unknown
- 2005-07-05 PT PT57619173T patent/PT1767221E/pt unknown
- 2005-07-05 SI SI200531802T patent/SI1767221T1/sl unknown
-
2007
- 2007-01-05 CU CU2007000002A patent/CU23917B1/es active IP Right Grant
-
2011
- 2011-07-14 US US13/182,634 patent/US8357375B2/en active Active
-
2012
- 2012-12-10 US US13/709,507 patent/US8916170B2/en active Active
-
2013
- 2013-11-20 CY CY20131101023T patent/CY1114673T1/el unknown
-
2014
- 2014-11-06 US US14/535,007 patent/US20150064212A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1767221T3 (da) | 2013-11-25 |
BRPI0513024A (pt) | 2008-04-22 |
EP1767221A2 (en) | 2007-03-28 |
US20150064212A1 (en) | 2015-03-05 |
PL1767221T3 (pl) | 2014-02-28 |
US20110318381A1 (en) | 2011-12-29 |
US8008457B2 (en) | 2011-08-30 |
US8357375B2 (en) | 2013-01-22 |
EP1767221B1 (en) | 2013-08-21 |
CA2573042C (en) | 2013-01-15 |
PT1767221E (pt) | 2013-11-27 |
MXPA04006617A (es) | 2006-01-12 |
US20130236478A1 (en) | 2013-09-12 |
PE20060377A1 (es) | 2006-05-05 |
CA2573042A1 (en) | 2006-01-12 |
US8916170B2 (en) | 2014-12-23 |
WO2006004390A3 (es) | 2006-09-21 |
CU23917B1 (es) | 2013-07-31 |
SI1767221T1 (sl) | 2014-01-31 |
US20080241183A1 (en) | 2008-10-02 |
AR049962A1 (es) | 2006-09-20 |
WO2006004390A2 (es) | 2006-01-12 |
ES2435769T3 (es) | 2013-12-23 |
CU20070002A7 (es) | 2009-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114673T1 (el) | Παρασκευη και χρηση δισθενους εμβολιου εναντιον εθισμου μορφινης-ηρωινης | |
Azmi et al. | Recent progress in adjuvant discovery for peptide-based subunit vaccines | |
Scheiblhofer et al. | Skin vaccination via fractional infrared laser ablation-Optimization of laser-parameters and adjuvantation | |
Weinberger et al. | Vaccines for the elderly | |
Alving et al. | Adjuvants for vaccines to drugs of abuse and addiction | |
Amorij et al. | Towards tailored vaccine delivery: needs, challenges and perspectives | |
ES2241042T3 (es) | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. | |
Arca et al. | Chitosan-based systems for the delivery of vaccine antigens | |
Kaurav et al. | Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage | |
ES2959398T3 (es) | Compuesto y método para vacunación e inmunización | |
CY1111916T1 (el) | Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος | |
WO2005097211A3 (en) | Compositions as adjuvants to improve immune responses to vaccines and methods of use | |
Mata et al. | Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research | |
Weeratna et al. | CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice | |
NO20015073D0 (no) | Vaksiner | |
US20150258190A1 (en) | Nicotinamide as adjuvant | |
Schulze et al. | New horizons in the development of novel needle-free immunization strategies to increase vaccination efficacy | |
Shende et al. | Combined vaccines for prophylaxis of infectious conditions | |
Simnani et al. | Nanocarrier vaccine therapeutics for global infectious and chronic diseases | |
Becker et al. | Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice | |
Corradin et al. | Novel adjuvants for vaccines | |
JP2016532712A (ja) | 薬物中毒に対するワクチン組成物 | |
Crothers et al. | Recent advances in enterotoxin vaccine adjuvants | |
Freytag et al. | Mucosal adjuvants: new developments and challenges | |
Kumar | A vaccine to prevent transmission of human malaria: a long way to travel on a dusty and often bumpy road |